Table 2.
Category | Macrolide resistance | Grand total | |||||||
Female | Male | ||||||||
Resistance (n=22) | Susceptible (n=23) | Total (n=45) | p Value | Resistance (n=30) | Susceptible (n=17) | Total (n=47) | p Value | ||
Median age (IQR) | 22 (20–26) | 26 (22–29) | 24 (20–28) | 0.04 | 29 (23–41) | 27 (25–40) | 28 (24–41) | 0.90 | 26 (22–31) |
Ethnicity | |||||||||
Caucasian | 10 (45.5) | 12 (54.5) | 22 (50.0) | 0.83 | 22 (75.9) | 14 (87.5) | 36 (80.0) | 0.80 | 58 (65.2) |
Indigenous | 6 (27.3) | 5 (22.7) | 11 (25.0) | 1 (3.4) | 0 | 1 (2.2) | 12 (13.5) | ||
Other | 6 (27.3) | 5 (22.7) | 11 (25.0) | 6 (20.7) | 2 (12.5) | 8 (17.8) | 19 (21.3) | ||
Sexual partners | |||||||||
Heterosexual | – | – | – | 14 (48.3) | 13 (81.3) | 27 (60.0) | 0.06 | – | |
Same sex | – | – | – | 15 (51.7) | 3 (18.8) | 18 (40.0) | – | ||
Testing location | |||||||||
Calgary | 5 (22.7) | 8 (34.8) | 13 (28.9) | 0.37 | 10 (33.3) | 9 (52.9) | 19 (40.4) | 0.19 | 32 (34.8) |
Edmonton | 17 (77.3) | 15 (65.2) | 32 (71.1) | 20 (66.7) | 8 (47.1) | 28 (59.6) | 60 (65.2) | ||
Symptomatic | |||||||||
No | 15 (68.2) | 14 (63.6) | 29 (65.9) | 0.75 | 15 (51.7) | 11 (68.8) | 26 (57.8) | 0.27 | 55 (61.8) |
Yes | 7 (31.8) | 8 (36.4) | 15 (34.1) | 14 (48.3) | 5 (31.3) | 19 (42.2) | 34 (38.2) | ||
HIV status | |||||||||
Negative | 19 (95.0) | 16 (80.0) | 35 (87.5) | 0.34 | 20 (71.4) | 8 (50.0) | 28 (63.6) | 0.11 | 63 (75.0) |
Positive | 0 | 0 | 0 | 2 (7.1) | 0 | 2 (4.5) | 2 (2.4) | ||
Unknown | 1 (5.0) | 4 (20.0) | 5 (12.5) | 6 (21.4) | 8 (50.0) | 14 (31.8) | 19 (22.6) | ||
Coinfections | |||||||||
Chlamydia | 3 (13.6) | 7 (30.4) | 10 (22.2) | 0.28 | 3 (10.0) | 2 (11.8) | 5 (10.6) | 1.00 | 15 (16.3) |
Gonorrhoea | 2 (9.1) | 2 (8.7) | 4 (8.9) | 1.00 | 2 (6.7) | 0 | 2 (4.3) | 0.53 | 6 (6.5) |
MPC/NGU | 0 | 0 | 0 | 6 (20.0) | 3 (17.6) | 9 (19.1) | 1.00 | – |
Missing data: ethnicity (female=1, male=2), symptomatic (female=1, male=2), HIV status (female=5, male=3), sexual partners=2.
MPC, mucopurulent cervicitis; NGU, non-gonococcal urethritis.